MEDNAX Inc
NYSE:MD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (8), the stock would be worth $21.48 (6% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.5 | $22.85 |
0%
|
| 3-Year Average | 8 | $21.48 |
-6%
|
| 5-Year Average | 9.2 | $24.68 |
+8%
|
| Industry Average | 19.2 | $51.63 |
+126%
|
| Country Average | 19.6 | $52.63 |
+130%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$1.8B
|
/ |
Jan 2026
$231.1m
|
= |
|
|
$1.8B
|
/ |
Dec 2026
$255m
|
= |
|
|
$1.8B
|
/ |
Dec 2027
$252.6m
|
= |
|
|
$1.8B
|
/ |
Dec 2028
$255.9m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
MEDNAX Inc
NYSE:MD
|
1.9B USD | 8.5 | 11.5 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
97.1B USD | 14 | 54.9 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
69.3B EUR | 9.9 | 13.4 | |
| US |
|
Cigna Corp
NYSE:CI
|
72.4B USD | 0 | 12.1 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.9B EUR | 14.2 | 18.9 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23B EUR | 16.8 | 23.5 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.4B USD | 16.5 | 22.7 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.4B USD | 17.7 | 25.5 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.9B EUR | 9.9 | 11.2 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.7B USD | -27.9 | -28.1 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 9.8 | 14 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
MEDNAX Inc
Glance View
MEDNAX Inc., a healthcare company often flying under the radar of typical mainstream attention, operates at the heart of the medical services industry by providing specialized services in neonatology, anesthesia, pediatrics, and radiology. Emerging from its inception in 1979, MEDNAX has carved out a unique footprint by associating with a network of physicians and advanced practitioners who deliver targeted services. The company orchestrates a seamless operation where these medical professionals are not merely standalone entities but integral components of a broader service platform. They engage in practices that fill a critical gap in the healthcare ecosystem: providing expertise-driven, high-touch care primarily in hospital settings, where the demand for precise and nuanced medical attention is the highest. Financially, MEDNAX derives revenue from agreements forged with hospitals and health systems, wherein these institutions pay for the specialized care delivery services. The company also taps into the insurance revenue stream, billing patients’ insurance providers for the medical services rendered. With a business model deeply embedded in partnerships, MEDNAX leverages its expansive nationwide network of clinicians to negotiate advantageous service agreements and efficiently manage the reimbursement landscape. By aligning its operational focus with key medical sectors that are consistently in need of expert intervention and by building a flexible, scalable service model, MEDNAX ensures its revenue streams remain robust while it continues to adapt to the vicissitudes of the healthcare industry.